Meeting
2020 ASCO Virtual Scientific Program
Will adding alkylating agent to bortezomib improve survival of newly diagnosed AL amyloidosis patients?
Authors
Yumeng Zhang
University of South Florida, Tampa, FL
Yumeng Zhang , Lauren Duncanson , Taiga Nishihori , Doris K. Hansen , Jose L. Ochoa-Bayona , Hien D Liu , Rachid C. Baz , Brandon Jamaal Blue
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Other
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8517)
DOI
10.1200/JCO.2020.38.15_suppl.8517
Abstract #
8517
Poster Bd #
417
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).
First Author: Saad Zafar Usmani
Poster
2020 ASCO Virtual Scientific Program
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
First Author: Stefan Knop
Poster
2020 ASCO Virtual Scientific Program
Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.
First Author: Robert F. Cornell
Poster
2018 ASCO Annual Meeting
Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.
First Author: Ray Comenzo